NEC ONCOIMMUNITY AS

Their core work

NEC Oncoimmunity is a Norwegian biotech SME specializing in AI-driven personalized cancer immunotherapy. Their core product is machine learning software that analyzes a patient's tumor genome via next-generation sequencing and predicts which neoantigens — tumor-specific mutations — are most likely to trigger a strong immune response, enabling the design of personalized cancer vaccines. The company operates at the intersection of computational biology, oncology, and artificial intelligence, translating genomic data into actionable vaccine targets. Their work addresses one of the central challenges in precision oncology: identifying the right epitopes to include in an individualized therapeutic vaccine without costly trial-and-error laboratory screening.

What they specialise in

How they've shifted over time

NEC Oncoimmunity's H2020 trajectory follows a textbook SME Instrument progression: a short feasibility phase in 2017 (MEDIVAC SME-1, €50K) with no publicly indexed keywords, followed by a full innovation project in 2019–2021 (MEDIVAC SME-2, €2.2M) where the technical stack — AI, NGS, neoantigen prediction, cancer vaccines — becomes explicit. The absence of early keywords reflects the exploratory, pre-product nature of the feasibility study, while the recent period shows a company that has crystallized its value proposition around a specific AI-powered pipeline. The trend is one of deepening specialization rather than broadening scope: they are doubling down on neoantigen prediction rather than expanding into adjacent areas.

NEC Oncoimmunity is on a focused product-development trajectory, moving from concept validation to a deployable AI platform for cancer vaccine design — making them a strong candidate for partnerships involving clinical validation, hospital integration, or pharmaceutical co-development.

How they like to work

NEC Oncoimmunity has consistently acted as project coordinator across both H2020 projects, suggesting a lead-and-deliver style rather than a supporting role in larger consortia. With zero recorded consortium partners in the available data, their EU projects appear to have been single-company innovation grants (SME Instrument), which is by design for that funding scheme — it reflects an inward-focused R&D model rather than a collaborative network preference. Organizations seeking a consortium partner should expect a confident, IP-protective startup that knows its technology well but may have limited experience in multi-partner coordination.

No consortium partners or cross-country collaborations are recorded in the H2020 data, consistent with NEC Oncoimmunity having used the SME Instrument — a single-beneficiary funding scheme. Their collaboration network in the EU project context is effectively the company itself, though clinical and research partnerships may exist outside the CORDIS record.

What sets them apart

NEC Oncoimmunity sits at a rare intersection: they are one of very few European SMEs with a dedicated AI platform specifically for neoantigen-based therapeutic vaccine design, as opposed to broader cancer genomics or generic immuno-oncology tools. Their back-to-back MEDIVAC grants indicate EU validation of both the concept and the team's execution capacity. For a consortium or company looking to add a computational cancer vaccine layer to a clinical or translational project, NEC Oncoimmunity brings a ready-made ML pipeline rather than a research prototype.

Highlights from their portfolio

• MEDIVAC (SME-2)
  The flagship project with €2.2M in EC funding represents one of the largest SME Instrument Phase 2 awards in personalized cancer immunotherapy, validating the commercial and scientific potential of the neoantigen prediction platform.
• MEDIVAC (SME-1)
  The Phase 1 feasibility study in 2017 is notable as the starting point of a successful two-stage EU funding journey, demonstrating the company's ability to build a compelling business case for AI-driven personalized oncology.